The MYSTIC surveillance program has documented discordance that favors imipenem as the more potent agent, compared to meropenem, for treatment of MDR Acinetobacter infection.[33] Efflux pumps may affect meropenem to a greater degree, whereas, specific beta-lactamases hydrolyze imipenem more efficiently.[33] Susceptibility testing of imipenem does not predict susceptibility to meropenem or vice versa.[33]. Here, LACTB is linked to Acinetobacter infectious disease.